Every Form 4 that Viridian Therapeutics, Inc. (VRDN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VRDN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VRDN filings page.
Viridian Therapeutics, Inc. (VRDN) reported that Chief Legal Officer Jennifer Tousignant exercised stock options and sold shares on August 19, 2026. She exercised options to acquire 10,000 shares of common stock at $14.41 per share, then sold a total of 14,212 shares of common stock at $24.50 per share in open-market or private transactions, including 718 shares previously acquired under the company’s Employee Stock Purchase Plan. Following the option exercise, 114,072 option shares remain outstanding under the reported grant, which was issued on March 3, 2025 and vests in 48 equal monthly installments through March 3, 2029, with an expiration date of March 3, 2035.
Viridian Therapeutics, Inc. (VRDN) reported that its Chief Medical Officer, Radhika Tripuraneni, exercised a stock option for 40,000 shares of common stock on 2026-08-14 at an exercise price of $13.21 per share. The exercised option, which was fully vested, now shows 0 derivative shares remaining, and her directly held common stock position increased to 40,000 shares following the transaction.
Viridian Therapeutics director-associated funds received a new stock option grant linked to board service. Investment vehicles managed by Fairmount Funds Management LLC were granted an option covering 32,341 shares of Viridian common stock at an exercise price of $18.48 per share. The option vests in full on the earlier of July 1, 2027 or the company’s 2027 annual meeting of stockholders, if Christopher W. Cain continues serving on Viridian’s Board of Directors. The option expires on July 1, 2036. Under Cain’s arrangement with Fairmount, any net cash or stock from the option must be turned over to the adviser for the benefit of the Fairmount funds, and Cain disclaims beneficial ownership of both the option and the underlying shares.
Viridian Therapeutics director Jeffrey Robert Ajer received a grant of stock options for 32,341 shares of common stock at an exercise price of $18.48 per share. These options were awarded as compensation and give him the right to buy shares in the future at that fixed price. The options vest in full on the earlier of July 1, 2027 or the company’s 2027 annual meeting of stockholders, if he continues serving on the board until that time. After this grant, he holds stock options covering 32,341 underlying shares directly.
Viridian Therapeutics director Jennifer K. Moses received a grant of stock options covering 32,341 shares of common stock. The options have an exercise price of $18.48 per share and expire on July 1, 2036. This is a compensation-related award, not an open-market purchase.
The option vests in full on the earlier of July 1, 2027 or the company’s 2027 annual stockholder meeting, as long as she continues serving on the board. After this grant, she holds 32,341 stock options directly according to this filing.
Viridian Therapeutics director Sarah Gheuens received a grant of stock options as part of her board compensation. She was awarded options for 32,341 shares of common stock with an exercise price of $18.48 per share, expiring on July 1, 2036. The options vest in full on the earlier of July 1, 2027 or the company’s 2027 annual meeting of stockholders, assuming she continues to serve on the board. After this grant, she holds options for 32,341 underlying shares directly.
Viridian Therapeutics director-associated funds received a new stock option grant. An option over 32,341 shares of Viridian common stock was granted at an exercise price of $18.48 per share and expires on July 1, 2036.
The option vests in full on the earlier of July 1, 2027 or Viridian’s 2027 annual stockholder meeting, contingent on Tomas Kiselak continuing to serve on the board. Under an arrangement with Fairmount Funds Management LLC, the option and any related value are for Fairmount-managed investment vehicles, and Kiselak disclaims beneficial ownership.
Viridian Therapeutics director Arlene Morris received a grant of 32,341 stock options. These options give her the right to buy an equal number of Viridian common shares at an exercise price of $18.48 per share and expire on July 1, 2036.
The option vests in full on the earlier of July 1, 2027 or Viridian’s 2027 annual meeting of stockholders, as long as she continues serving on the company’s Board of Directors. After this grant, she holds 32,341 derivative securities directly.
Viridian Therapeutics insider entities reported a large open-market share purchase. On May 11, 2026, Fairmount Healthcare Fund II L.P. bought 1,176,470 shares of Viridian common stock at $17.00 per share in an open-market transaction. After this trade, the fund’s indirect holdings reported in the filing totaled 5,090,928 shares.
Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting and investment power over the shares held by Fairmount Healthcare Fund II L.P., but each disclaims beneficial ownership except to the extent of any pecuniary interest.
Viridian Therapeutics Chief Financial Officer files an amended insider transaction report reflecting tax-related share withholding. On the corrected Form 4/A, Seth Harmon is shown disposing of 2,031 shares of Viridian common stock on March 3, 2026 at $30.19 per share to cover tax obligations. Following this tax-withholding disposition, he beneficially owns 7,850 shares of common stock. The amendment updates both the number of shares and the price used to satisfy taxes, as well as the resulting total holdings, compared with the initial Form 4 filed on March 4, 2026.
Viridian Therapeutics Chief Operating Officer Thomas W. Beetham filed an amended insider report updating a prior Form 4. The amendment corrects the number of shares and price involved in a tax-withholding disposition of 3,048 shares of common stock at $30.19 per share on a transaction coded “F.”
These shares were withheld to cover taxes, rather than sold in an open-market trade. After this correction and all transactions reported in the original Form 4, Beetham is shown as beneficially owning 13,361 shares of Viridian Therapeutics common stock directly.
Viridian Therapeutics Chief Legal Officer updates prior tax-related share filing. Jennifer Tousignant filed an amended Form 4 to correct the number of shares and price previously reported as disposed to cover taxes. The amendment now shows a tax-withholding disposition of 1,675 shares of common stock at $30.19 per share on March 3, 2026, leaving her with 3,494 shares of Viridian Therapeutics common stock held directly.
Viridian Therapeutics President and CEO Stephen F. Mahoney disposed of 7,408 shares of common stock on March 3, 2026 at $30.19 per share to cover taxes. This amended Form 4 corrects the share and price figures previously reported and shows he beneficially owns 33,349 shares afterward.
Viridian Therapeutics’ Chief Legal Officer Jennifer Tousignant reported multiple equity compensation transactions. On March 2, 2026, she received a grant of stock options for 119,300 shares and 23,850 restricted stock units, each RSU representing one share of common stock. The option grant vests in 48 equal monthly installments after the grant date, while the RSUs vest over four years, with 25% vesting on each yearly anniversary of the grant date, subject to continued service.
On March 3, 2026, 5,169 RSUs vested and were converted into 5,169 shares of common stock. In connection with this vesting, 1,724 shares of common stock were disposed of at $29.32 per share to cover tax withholding obligations. After these transactions, she directly held 15,510 RSUs and 3,445 shares of common stock.
Viridian Therapeutics Chief Financial Officer Seth Harmon reported multiple equity compensation moves. On March 2, 2026 he received a stock option covering 102,850 shares and 20,550 restricted stock units, each at a stated price of $0.00 per share. On March 3, 2026, 6,267 RSUs converted into common stock and 2,091 shares of common stock were withheld at $29.32 per share to cover taxes, leaving him with 7,790 common shares held directly.
Viridian Therapeutics’ Chief Financial Officer Seth Harmon filed an amended Form 4 to correct his reported share ownership. The amendment explains that a prior Form 4 filed on March 4, 2025 inadvertently omitted 1,711 shares purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan.
After reflecting these previously purchased shares, Harmon is shown as directly beneficially owning 1,711 shares of Viridian Therapeutics common stock. The filing does not report any new transactions, but updates the accuracy of his disclosed holdings.
Viridian Therapeutics, Inc. officer Jennifer Tousignant filed an amended Form 4 to correct her reported holdings. The prior filing inadvertently left out 610 shares that were purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan. After this correction, she is shown as directly owning 610 common shares.
Viridian Therapeutics Chief Operating Officer Thomas W. Beetham reported multiple equity award transactions. On March 2, 2026, he received a stock option grant for 176,550 shares vesting in 48 equal monthly installments, and 35,300 Restricted Stock Units (RSUs) vesting 25% annually over four years.
On March 3, 2026, 9,409 RSUs converted into the same number of common shares, and 3,138 common shares were disposed of at $29.32 per share to cover tax obligations. Following these transactions, he directly held 13,271 common shares and 28,227 RSUs.
Viridian Therapeutics President and CEO Stephen F. Mahoney reported multiple equity award transactions. On March 2, 2026, he was granted stock options for 559,600 shares that vest in 48 equal monthly installments after the grant date, and 111,900 restricted stock units (RSUs) that vest in four annual installments starting March 2, 2026.
On March 3, 2026, 18,357 RSUs converted into an equal number of common shares as part of a prior grant that vests annually from March 3, 2025. To cover tax obligations, 7,627 common shares were disposed of at $29.32 per share through tax withholding, leaving 33,130 common shares held directly.
Viridian Therapeutics Chief Medical Officer Radhika Tripuraneni reported equity awards consisting of stock options and restricted stock units. She acquired stock options for 95,800 shares at an exercise price of $0.00 per share, with the grant dated March 2, 2026. These options vest in 48 equal monthly installments, conditioned on continued service. She also received 19,150 restricted stock units, each representing one share of common stock. The RSUs vest over four years, with 25% vesting on each yearly anniversary of the March 2, 2026 grant date, also subject to continued service.
Viridian Therapeutics, Inc. insider Jennifer Tousignant, the company’s Chief Legal Officer, reported a transaction in the company’s common stock. On 12/31/2025, she disposed of 2,272 shares of Viridian common stock at a price of $31.16 per share, coded as a sale. Following this transaction, the filing lists her as beneficially owning 0 shares directly. The footnote explains that the reported shares consist of stock purchased under Viridian’s employee stock purchase plan.
Viridian Therapeutics (VRDN) reported an insider purchase on a Form 4. On 10/23/2025, Fairmount Healthcare Fund II LP acquired 454,545 shares of common stock at $22 per share (transaction code P). Following the trade, the fund beneficially owned 3,914,458 shares, held indirectly.
Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting and investment power over the securities held by Fairmount Healthcare Fund II LP, and they disclaim beneficial ownership except to the extent of their pecuniary interest. The reporting persons are indicated as a Director and 10% Owner, and the form was filed by more than one reporting person.